The Patent Finder

Site-Specific Chemoenzymatic Protein Modifications

Novartis AG

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 3 of these applications claim priority to application 61/883,050, filed Sep 26, 2013. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 9,084,781Mek Mutations Conferring Resistance to Mek Inhibitors
In force
 · High confidence
UsedRemaining
Dana-Farber Cancer Institute, Inc.In forceHigh confidence
US 9,540,619MELK Regulation for the Treatment of Breast Cancer
In force
 · High confidence
Novartis AGIn forceHigh confidence
US 9,359,400Site-Specific Chemoenzymatic Protein Modifications
In force
 · High confidence
Novartis AGIn forceHigh confidence
US 10,975,120Site-Specific Chemoenzymatic Protein Modifications
In force
 · High confidence
Novartis AGIn forceHigh confidence
US 9,540,324Selective Octahydro-Cyclopenta[c] Pyrrole Negative Modulators of NR2B
In force
 · High confidence
Novartis AGIn forceHigh confidence
US 11,116,749Selective Octahydro-Cyclopenta[c]pyrrole Negative Modulators of NR2B
In force
 · High confidence
Novartis AGIn forceHigh confidence
US 10,239,835N-ALKYLARYL-5-Oxyaryl-OCTAHYDRO-CYCLOPENTA[C]PYRROLE Negative Allosteric Modulators of NR2B
In force
 · High confidence
Novartis AGIn forceHigh confidence
US 10,781,174N-ALKYLARYL-5-Oxyaryl-OCTAHYDRO-CYCLOPENTA[C]PYRROLE Negative Allosteric Modulators of NR2B
In force
 · High confidence
A.O. International II, Inc.In forceHigh confidence
US 12,145,909N-ALKYLARYL-5-Oxyaryl-OCTAHYDRO-CYCLOPENTA[C]PYRROLE Negative Allosteric Modulators of NR2B
In force
 · High confidence
Novartis AGIn forceHigh confidence
US 12,161,624Selective Octahydro-Cyclopenta[c]pyrrole Negative Modulators of NR2B
In force
 · Medium confidence
Novartis AGIn forceMedium confidence
6 more records in this group · Pro
10 of 16 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 16, including 1 expired.
Upgrade to Pro
8 of these are in force and held by Novartis AG.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited